Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals and keeping the price target at $5.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes has given his Buy rating due to a combination of factors, primarily centered around the potential approval and launch of Cardamyst, a nasal spray for paroxysmal supraventricular tachycardia (PSVT). The anticipated approval in December 2025 positions Cardamyst as a first-to-market, at-home therapy that could significantly transform patient care and reduce healthcare burdens. Additionally, Milestone Pharmaceuticals has strengthened its financial position, providing the necessary resources to support a successful product launch.
Moreover, the company has addressed previous regulatory concerns, leading to the FDA’s acceptance of their resubmitted NDA. This swift resolution indicates that the issues were manageable and unlikely to impede the December approval. The potential for Cardamyst to outperform market expectations, coupled with the promising AFib-RVR program, suggests that Milestone Pharmaceuticals’ stock could significantly outperform its peers in the coming years.
According to TipRanks, Folkes is an analyst with an average return of -1.2% and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Eupraxia Pharmaceuticals, and Achieve Life Sciences.